ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source of BCG.” Specifically, the company will now be able to provide this ...
We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
ImmunityBio, Inc. (NASDAQ:IBRX) surged by 16.42 percent on Wednesday to end at $3.9 apiece as investors cheered news that it was authorized by the Food and Drug Administration (FDA) to help ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback